Study On The Correlation Between Plasma MicroRNA143/145 And Acute Coronary Syndrome

Background and Objective:The main pathogenesis of acute coronary syndrome(ACS)is coronary arteries unstable plaque rupture leads to adhesion,aggregation and activation of platelets,and thrombosis formation.Abnormal lipid metabolism,platelet activation,and inflammatory response are regulatory pathways in the development of ACS.Their interactions are interrelated.The abnormal proliferation of vascular smooth muscle cells plays an important role in the formation of plaque.MicroRNA(miRNA)is a small non encoding RNA which length is about 21-23nt of the single stranded small RNA.It is not translated into protein,mainly by combining with the molecular target of mRNA gene at the post transcriptional level to regulate the gene transcription and translation.And participate in the regulation of cell growth and differentiation migration and apoptosis.At present,many kinds of microRNA have been found to participate in the development of cardiovascular diseases,tumors and some metabolic diseases.Some of them play an important role in cardiovascular diseases.MiRNAs plays an important role in cardiovascular diseases.A large number of studies have shown that a variety of MicroRNAs participates in the phenotype transformation of vascular smooth muscle cells during the formation of atherosclerotic plaque.MicroRNA143 and microRNA145 have been extensively studied to confirm that vascular smooth muscle cells can be transformed from undifferentiated phenotypes to differentiated phenotypes,and play a regulatory role in plaque formation.The aim of this study is to explore the possible role of microRNA143/145 in the diagnosis of ACS by comparing the changes of plasma level of plasma between the acute coronary syndrome group and the normal control group.The microRNA in plasma has a certain tissue specificity and is expected to be a new biological marker,which has a certain auxiliary role in the diagnosis of ACS.Moreover,in recent years,many studies have found that microRNA can not only serve as a biomarker,but also can be used as a therapeutic target for clinical diagnosis and treatment.So microRNA143 and microRNA145 are also expected to become new targets for diagnosis and treatment of ACS.To investigate the expression and clinical significance of microRNA-143(miR-143)and microRNA-145(miR-145)in plasma in patients with acute coronary syndrome(ACS).Methods:Fourty-five patients in Haici Hospital during 2017 September to 2018 January were selected and divided into ACS group(n=30),control group(n=15).Then the ACS group was divided into acute myocardial infarction(AMI)group(n= 15),unstable angina pectoris(UAP)group(n=15)based on clinical diagnosis.Real-time PCR was applied to detect the expression of microRNA143 and microRNA145 in plasma.And compare the gender,age,smoking history,triglyceride,cholesterol,low density lipoprotein,high-density lipoprotein,fasting blood glucose and history of hypertension.Results:① Compared with control group,the microRNA143 and microRNA 145 level was lower in UAP group(P<0.05).②Compared with control group,the microRNA143 and microRNA 145 level was lower in AMI group(P<0.05).③ Compared with UAP group and AMI group,the microRNA143 and microRNA 145 level were no significant difference.(P>0.05).④ Compared with three groups the gender,age,smoking history,triglyceride,cholesterol,low density lipoprotein,high-density lipoprotein,fasting blood glucose and history of hypertension without significant difference(P>0.05).Conclusions:The ACS group expresion level of miR-143 and miRNA-145 lower in plasma,which suggest that they can play important roles in the occurrence and development of ACS,and expected to become the ACS diagnosis and treatment target.